Brian DiDonato

ADAXION Therapeutics is transforming the future of biotherapeutics by tackling one of the biggest challenges in drug development: immunogenicity. Based in San Diego, the company is developing innovative treatments for immune-mediated and inflammatory diseases using its proprietary ADAx platform. This technology is designed to deimmunize protein therapeutics—preventing the formation of anti-drug antibodies (ADAs) that can compromise efficacy and trigger harmful immune responses. The ADAx platform uses proprietary CD22 ligands to selectively eliminate therapeutic-specific B cells while preserving the full functionality of the biologic and maintaining overall immune competence. This drug-specific approach enables the development of first- and best-in-class biologics that would otherwise be limited by immunogenicity. With a growing pipeline and a focus on addressing unmet medical needs, ADAXION is unlocking the full potential of biologics to enhance therapeutic performance and expand their clinical impact.